Skip to main content
Download PDF

Kynureninase knockdown inhibits cisplatin resistance in vivo and in vitro and impacts the prognosis of cervical adenocarcinoma

Cell Division volume 18, Article number: 15 (2023) Cite this article

Abstract

Background

Chemotherapy resistance is a leading cause of treatment failure in cases of cervical adenocarcinoma (ADC), and no effective treatment approach has yet been found. We previously identified the differentially expressed kynureninase (KYNU) mRNA in cervical adenocarcinoma cells (HeLa) and cervical adenocarcinoma cisplatin resistance cells (HeLa/DDP) using gene chips. However, the role and potential mechanism of KYNU in the cisplatin resistance of cervical adenocarcinoma remain unclear.

Methods

We verified the expression of KYNU in the cells and tissues of ADC patients and analyzed its correlation with patient prognosis. A stable HeLa/DDP cell line with KYNU mRNA knockdown was constructed. We then used a CCK8 assay to detect cell survival, a transwell assay to evaluate cell migration and proliferation and flow cytometry to measure apoptosis. The effect of KYNU silence on cisplatin sensitivity was evaluated in an orthotopic model of metastatic ADC. Immunohistochemistry was performed to determine the changes in relevant drug resistance-associated protein expression, aiming to explore the underlying mechanism of KYNU-mediated drug resistance.

Results

KYNU is overexpressed in HeLa/DDP cells and tissues and is associated with the poor prognoses of patients with ADC. After KYNU mRNA knockdown, the invasion, migration, and proliferation of HeLa/DDP cells in the cisplatin environment significantly reduced, while the apoptosis rate of HeLa/DDP cells significantly increased. Meanwhile, KYNU knockdown improved the DDP sensitivity of ADC in vivo. Furthermore, silencing KYNU decreased the expressions of CD34 and the drug-resistance related proteins P-gp, MRP1, and GST-π and increased the level of the proapoptotic regulatory protein Bax.

Conclusion

KYNU deficiency enhanced DDP sensitivity by suppressing cell proliferation, migration, and invasion and promoting apoptosis in DDP-resistant ADC cells in vitro. Furthermore, KYNU knockdown improved the drug sensitivity of ADC in vivo. The results showed that KYNU is involved in the chemotherapy resistance of cervical adenocarcinoma.

Introduction

Cervical cancer is one of the most common malignancies in women and is a serious public health problem in developing countries [1, 2]. With effective screening, the early detection rate of cervical cancer has greatly increased, and its overall morbidity and mortality have decreased; however, the rising incidence and younger onset of cervical adenocarcinoma (ADC) cannot be ignored [3, 4]. Cisplatin-based concurrent chemoradiotherapy is the standard treatment for locally advanced cervical adenocarcinoma. However, cervical ADC has low sensitivity to radiotherapy. In advanced ADC patients who are resistant to cisplatin-based chemotherapy treatment, there is currently no standardized treatment plan for second-line or subsequent treatments, resulting in a very poor prognosis.

Considering the difficulties of clinical treatment, we previously investigated the differential expression of kynureninase (KYNU) mRNA in cervical adenocarcinoma cells (HeLa/DDP) and cervical adenocarcinoma cisplatin-resistant cells (HeLa/DDP) using gene chips. KYNU is a key enzyme in the metabolic pathway of tryptophan. A large number of studies have shown that KYNU plays an important role in carcinogenesis, progression, and chemoresistance [5,6,7]. However, the role and potential mechanism of KYNU in cisplatin resistance and the malignant progression of cervical ADC remain unclear. In this study, we explored the role of KYNU in the cisplatin resistance of cervical ADC, aiming to provide a theoretical basis for overcoming this resistance and improving the prognoses of patients with cervical ADC.

Materials and methods

Tissue samples

A total of 53 paraffin specimens of biopsy tissue were collected from patients with Stage I b1 to Stage II b ADC who received two cycles of platinum-based neoadjuvant chemotherapy at Jiangxi Maternal and Child Health Carehospital. Based on Response Evaluation Criteria in Solid Tumours 1.1 (RECIST1.1), the 53 patients were divided into a DDP-sensitive group (n = 20) and a DDP-resistant group (n = 33). Immunohistochemistry (PV-9000) was performed to determine the expression of KYNU in the biopsy tissues.

Cell culture

Human cervical adenocarcinoma HeLa cells were preserved in the central laboratory of Jiangxi Maternal and Child Health Hospital. Human cervical ADC cisplatin-resistant HeLa/DDP cells were successfully constructed by our research group in 2014 and stored in a liquid nitrogen tank. HeLa and HeLa/DDP cells were maintained in a DMEM medium (Gibco, UK) supplemented with 10% v/v fetal bovine serum FBS (Gibco, UK). All cell lines were maintained in 37 °C incubators Femented with 5% CO2. The HeLa/DDP cells were resuscitated, and stepwise dosing was performed once the cell density was above 70%; the DDP concentrations were 0.2 μg/mL, 0.5 μg/mL, 0.75 μg/mL, and 1 μg/mL. Once the cell state was stable, cisplatin resistance was maintained with 1 μg/mL DDP.

Lentiviral shRNA-mediated KYNU mRNA knockdown

The HeLa/DDP cells were transfected with the GV248-KYNU lentivirus, involving KYNU mRNA knockdown and the empty vector lentivirus GV248-NC (GenePharma, Shanghai, China). The lentivirus carries a reporter gene—green fluorescent protein (GFP)—which was used to determine transfection efficiency.

RT-qPCR

Total RNA was extracted from the HeLa and Hela/DDP cells using TRIzol (Invitrogen) and reverse-transcribed to the first-strand cDNA. Quantitative real-time PCR (qPCR) was performed using a StepOnePlus™ real-time PCR system (Applied Biosystems™). The qPCR conditions were as follows: 95 °C for 30 s; 40 cycles of 95 °C for 5 s and 60 °C for 30 s. Quantification was performed using the comparative Ct (ΔΔCt) method according to the manufacturer’s instructions.

Western blot

Proteins were extracted from the HeLa and Hela/DDP cells using RIPA buffer and qualified using a BCA kit (Solarbio). The proteins were separated via SDS-PAGE and then moved to PVDF membranes. After being blocked with skimmed milk, the target proteins were incubated with primary antibodies, namely anti-KYNU (Abcam, Cambridge, USA.) and anti-P-gp (Abcam, Cambridge, USA). Secondary antibodies were added for 1 h. Finally, the proteins were examined using a chemiluminescence detection system.

Transwell assay assay

Matrigel, melted into liquid form, was mixed with a serum-free medium at a ratio of 1:8, and 50 μl of the mixture was taken for each well of a 96-well microplate. The wells were placed in a 5% CO2 incubator overnight at 37 °C. Then, 200 μl of the cell suspension (1 × 105/ml) was added to the upper chamber, and 500 μl of the medium containing 10% FBS was added to the lower chamber. After incubation in a 5% CO2 incubator for 48 h, the cells in the lower layer of the microporous membrane were counted using an optical microscope (100×). The mean cell counts of 10 randomly selected fields were determined.

Migration assay

The cells were incubated for 24 h in a 5% CO2 incubator. They were then stained with crystal violet and photographed under an optical microscope (100×). The numbers of cells in the lower layer of the microporous membrane were counted for 10 randomly selected fields, and the mean values were calculated.

Cell counting kit-8 (CCK-8) assay

HeLa and HeLa/DDP cells in the logarithmic growth phase were inoculated into 96-well plates (2 × 103 per well). After 24 h, the cells were treated with various concentrations of DDP. A blank group (without cells and DDP) and a control group (without DDP) were included. All experiments were performed in triplicate. After 72 h of incubation, 100 μl of fresh medium was added to the samples. Then, after 2 h, absorbance was measured at 490 nm.

In vivo tumor xenograft

Animal studies were performed according to the rules for care and use of experimental animals and were approved by the Animal Care Committees Nanchang University (approval numbers: SYXK(赣)2015–0001). A total of 32 female BAlB/c mice were randomly divided into four groups—GV248-KYNU-cisplatin, GV248-NC-cisplatin, HeLa/DDP-cisplatin, and HeLa/DDP-normal saline (NS)—according to whether cisplatin chemotherapy was to be performed. GV248-KYNU and GV248-NC cells were injected subcutaneously into the right axilla of the mice in the first two groups, respectively, and HeLa/DDP cells were injected into the other mice. Once the tumor xenograft grew to about 100 mm3, cisplatin chemotherapy was performed intraperitoneally at a dose of 3 mg/Kg every other day for a total of seven days. The volume of the transplanted tumor and the weight of each mouse were measured every three days until their natural deaths. Then, the mice were dissected to determine whether there was tumor metastasis. The tumor specimens were removed for paraffin sectioning, and the pathological changes of the transplanted tumors were observed using hematoxylin–eosin (HE)staining. Immunohistochemistry was performed to detect the expression levels of KYNU, P-gp, GST-π, MRP1, Bax, Bcl-2, and CD34.

Statistical methods

Quantitative data were recorded as mean ± standard deviation (SD) values. The differences among the groups were analyzed using the Student t-test. The Kaplan–Meier method was used to calculate the survival rate, and a log-rank test was performed to determine the significance of the differences in the survival distribution. P value less than 0.05 was defined as statistically significant.

Results

KYNU was overexpressed in the HeLa/DDP cells and tissues

The gene microarray (Affymetrix human transcript HTA2.0 mRNA) showed that the greatest difference between the HeLa and HeLa/DDP cells was in the expression of KYNU mRNA (P < 0.05, Table 1). Compared to the HeLa cells, KYNU mRNA expression was high in the HeLa/DDP cells (P < 0.05, Fig. 1a). The Western blot results revealed the over-expression of KYNU protein in the HeLa/DDP cells compared to the HeLa cells (Fig. 1b). Further, the expression of KYNU was slightly higher in the DDP-resistant ADC tissues than in the DDP-sensitive ADC tissues (P > 0.05, Table 2, Fig. 1c–d), and the Kaplan–Meier survival analysis indicated that ADC patients with higher KYNU expre

Table 1 The top five differentially expressed genes of HeLa and HeLa/DDP in the gene microarray
Full size table

ssion levels had worse prognoses (Fig. 1e–f).

Fig. 1
figure 1

Increased KYNU expression in HeLa/DDP cells and tissues. a KYNU mRNA in the HeLa and HeLa/DDP cells. b KYNU protein in the HeLa and HeLa/DDP cells (the samples derive from the same experiment and that gels/blots were processed in parallel). c KYNU protein in the DDP-resistant tissues (+ + +). d KYNU protein in the DDP-sensitive tissues ( +). e Progression-free survival analysis of high and low KYNU expression. f Overall survival analysis of high and low KYNU expression. *P < 0.05

Full size image
Table 2 The expression levels of KYNU protein in DDP-resistant and DDP-sensitive ADC tissues
Full size table

KYNU mRNA knockdown influences the invasion, migration, proliferation, and apoptosis rate of HeLa/DDP cells in a cisplatin environment

We used a lentivirus to create a Hela-DPP derivative cell line with shRNA-mediated stable KYNU mRNA knockdown. KYNU mRNA knockdown cell lines (GV248-KYNU) and negative control cell lines (GV248-NC) showed green fluorescence 24 h after lentivirus infection, and fluorescence expression was the strongest 72 h later. The transfection efficiency was 99% after screening with 2 μg/mL puromycin (Fig. 5). The expression levels of KYNU and P-gp protein were significantly lower in the GV248-KYNU group than in the HeLa/DDP and GV248-NC groups, and the differences were statistically significant (P < 0.05). There were no significant differences between the GV248-NC and HeLa/DDP groups with respect to the expression levels of KYNU and P-gp protein (P > 0.05, Fig. 2).

Fig. 2
figure 2

KYNU and P-gp expression (cropped gels, but the samples derive from the same experiment and that gels/blots were processed in parallel.) levels in the GV248-KYNU, GV248-NC, and HeLa/DDP cells. *P < 0.05, when compared to HeLa/DDP, #P < 0.05, when compared to GV248-NC

Full size image

After KYNU mRNA knockdown, the invasion, migration, and proliferation of HeLa/DDP cells in the cisplatin environment significantly reduced (P < 0.05), and their apoptosis rate significantly increased (P < 0.05, Fig. 3).

Fig. 3
figure 3

Effects of KYNU knockdown on HeLa/DDP cell proliferation (a), invasion (b), migration (c), and apoptosis (d)

Full size image

KYNU knockdown improved the DDP sensitivity of ADC in BALB/c mice injected with GV248-KYNU cells

Effect of KYNU knockdown on DDP sensitivity of ADC in BALB/c mice injected with GV248-KYNU

A mouse model of subcutaneous transplanted tumors was successfully constructed in this study. When the transplanted tumors grew to about 100 mm3, cisplatin chemotherapy was intraperitoneally performed at a dose of 3 mg/Kg every other day for a total of seven days. The mice in the HeLa/DDP-NS group, which were intraperitoneally injected with normal saline, showed the fastest tumor growth rate and the largest tumor volume. The mice in the GV248-KYNU-cisplatin group had the slowest tumor growth rate and the smallest tumor size, and the differences were statistically significant compared to the HeLa/DDP and GV248-NC groups (P < 0.05). Notably, there were no significant differences between the GV248-NC-cisplatin and HeLa/DDP-cisplatin groups in terms of tumor growth rate and volume (P > 0.05) (Table 3, Fig. 4  ).

Table 3 Volume of transplanted tumors at different time points (mm3)
Full size table
Fig. 4
figure 4

Effects of KYNU mRNA knockdown on the growth of mice. a The volume of transplanted tumors at different time points. b The volume of transplanted tumors on the 29th day after chemotherapy. *P < 0.05, when compared to HeLa/DDP, #P < 0.05, when compared to GV248-NC

Full size image

Effects of KYNU mRNA knockdown on the survival of mice after chemotherapy

The natural mean survival period of the mice was 210 days, and the mean survival of the mice that underwent chemotherapy without HeLa/DDP cell transplantation was 124 days. The mean survival periods of the mice in the HeLa/DDP-NS, HeLa/DDP-cisplatin, GV248-NC, and GV248-KYNU groups were 75, 76, 79, and 80 days, respectively. There were no significant differences in body weight or overall survival time between the HeLa/DDP-cisplatin, GV248-KYNU-ciplatin, and GV248-NC-cisplatin groups (Fig. 5).

Fig. 5
figure 5

Effects of KYNU mRNA knockdown on the weight a and survival b of mice after chemotherapy. Blank: Mice without any interference. Cisplatin: Mice that underwent chemotherapy but without HeLa/DDP cell transplantation. *P < 0.05, when compared to HeLa/DDP, #P < 0.05, when compared to GV248-NC

Full size image

Effects of KYNU mRNA knockdown on the morphology of HE staining in tumor-bearing mice after cisplatin chemotherapy

The mice were dissected to observe whether there was any tumor metastasis. The tumor specimens were removed for paraffin sectioning, and pathological changes in the transplanted tumors were observed via HE staining. No tumor metastasis was observed in any of the groups. The mice in the GV248-KYNU-cisplatin group showed lighter nuclear staining, smaller tumor nests, less atypia, and more nuclear mitosis, flake coagulation, and focal necrotic substances than the mice in the other three groups. However, the HeLa/DDP-NS, HeLa/DDP-cisplatin, and GV248-NC groups had more tumor cells, vigorous growth, and nuclear mitosis and more abundant cancer nests than the GV248-KYNU-cisplatin group (Fig. 6).

Fig. 6
figure 6

HE staining of the transplanted tumors of mice in each group

Full size image

Effect of KYNU knockdown on the expression of P-gp, MRP1, GST-π, Bax, Bcl-2, and CD34 protein

After KYNU mRNA knockdown, KYNU, CD34, and the drug-resistance related proteins P-gp, MRP1, and GST-π in the GV248-KYNU-cisplatin group were significantly downregulated compared to the HeLa/DDP-cisplatin and GV248-NC-cisplatin groups (P < 0.05). The expression level of the proapoptotic regulatory protein Bax was significantly higher in the GV248-KYNU-cisplatin group than in the HeLa/DDP-cisplatin and GV248-NC-cisplatin groups (P < 0.05). The antiapoptotic protein Bcl-2 was upregulated a little more in the GV248-KYNU-cisplatin group than in the other two groups, but the difference was not statistically significant (Fig. 7).

Fig. 7
figure 7

The expression levels of KYNU, P-gp, MRP1, GST-π, Bax, Bcl-2, and CD34 proteins in tumor-bearing mouse tissues. *P < 0.05, when compared to HeLa/DDP, #P < 0.05, when compared to GV248-NC

Full size image

Discussion

Chemoresistance is a leading cause of chemotherapy failure in cervical ADC, but currently there is a lack of effective treatment options. Abnormal metabolism is one of the basic characteristics of a tumor. Changes in metabolic pathways and metabolites regulate the life activities of tumor cells through mechanisms such as transcription, translation, posttranslational modification, and microenvironment changes, which, in turn, play crucial roles in inflammation, neurogenic diseases, tumor development, and drug resistance [8, 9]. KYNU is a key enzyme in the tryptophan pathway, through which more than 90% of human tryptophan is metabolized [10]. In recent years, the tryptophan–kynurenine pathway has received a lot of attention due to the immunosuppressive and cancer-promoting effects of its key enzymes and metabolites [11, 12]. In addition, a large number of studies have shown that KYNU plays an important role in carcinogenesis, tumor progression, and chemoresistance.

Gao et al. [13] reported that KYNU expression is closely related to the prognosis of pediatric acute lymphoblastic leukemia. The higher the expression, the worse the prognosis, indicating that KYNU is a carcinogenic factor in pediatric acute lymphoblastic leukemia. Ci et al. [14] found that a knockdown of KYNU expression could inhibit the proliferation of cutaneous squamous cell carcinoma by inhibiting the PI3K/AKT signaling pathway. Moreover, Li et al. [7] used gene chips to detect differentially expressed genes in drug-resistant and drug-sensitive samples of laryngeal cancer. Their results showed that KYNU was significantly upregulated in the chemotherapy-resistant group, and a receiver operating characteristic curve (ROC) analysis showed that KYNU was a good chemotherapy sensitivity index. In the present study, KYNU was overexpressed in HeLa/DDP cells and tissues and was associated with the poor prognoses of patients with ADC. After KYNU knockdown, the cisplatin sensitivity of nude mice with transplanted tumors increased, and the tumor growth rate slowed down. This indicates that KYNU is involved in the chemotherapy resistance of cervical ADC. Our results are consistent with the experimental results of the studies mentioned above. Notably, Liu et al. [15] found lower KYNU expression in breast cancer tissues than in lymphoid tissues and benign breast disease tissues. Furthermore, KYNU expression in breast cancer tissues was positively correlated with estrogen and progesterone receptor and negatively correlated with HER2 and Ki-67 expression, tumor size, and clinical stage. In addition, MTT assay results showed that highly expressed KYNU could inhibit the proliferation and migration of breast cancer cells, suggesting that KYNU is a tumor suppressor gene in breast cancer; this may be related to differences in tumor species and pathological patterns.

The proapoptotic regulatory protein Bax and the antiapoptotic regulatory protein Bcl-2 play important roles in cell apoptosis and drug resistance. In ovarian cancer cells, the downregulation of Bax and upregulation of Bcl-2 are associated with cisplatin resistance [16]. Bax mRNA has been found to be significantly downregulated in fluorouracilresistant colorectal cancer cells compared to wild-type HT-29 cells, suggesting that Bax is closely related to 5-FU resistance in colorectal cancer [17]. Decreased Bax/Bcl-2 ratio and caspase activity are the main mechanisms that cause the malignant glioblastoma cell line U87MG to be resistant to temozolomide (TMZ) [18] and the breast cancer cell line MCF-7 to be resistant to paclitaxel [19]. Bax mutations can also cause multidrug resistance [20]. In our study, the expression of the proapoptotic regulatory protein Bax was significantly upregulated after KYNU mRNA knockdown, the expression of the antiapoptotic protein Bcl-2 was slightly downregulated, and the Bax/Bcl-2 ratio increased. Furthermore, the expressions of the drug resistance-related proteins P-gp, MRP1, and GST-π were significantly downregulated, indicating that KYNU contributes to chemoresistance and the malignant progression of cervical ADC by regulating the expression of Bax.

In conclusion, KYNU deficiency could enhance DDP sensitivity by suppressing cell proliferation, migration, and invasion and promoting apoptosis in DDP-resistant ADC cells in vitro. KYNU knockdown improved the drug sensitivity of ADC samples in vivo. Thus, KYNU is involved in the chemotherapy resistance of cervical adenocarcinoma.

Availability of data and materials

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

References

  1. Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–206. https://doi.org/10.1016/S2214-109X(22)00501-0.

    Article  CAS  PubMed  Google Scholar 

  2. Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health. 2021;21(1):1329. https://doi.org/10.1186/s12889-021-11401-8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States [J]. Prev Med. 2019;123:316–23. https://doi.org/10.1016/j.ypmed.2019.04.010.

    Article  PubMed  Google Scholar 

  4. Baldur-Felskov B, Munk C, Nielsen TS, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012[J]. Cancer Causes Control. 2015;26(8):1105–16. https://doi.org/10.1007/s10552-015-0603-7.

    Article  PubMed  Google Scholar 

  5. Fahrmann JF, Dennison J, Murage E, et al. Elevated kynureninase protein expression is associated with KEAP1 mutant non-small cell lung cancer and is predictive of poor overall survival [J]. Cancer Res. 2016;76(14):Abstract LB-311.

    Article  Google Scholar 

  6. Al-Mansoob M, Gupta I, Stefan Rusyniak R, et al. KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion [J]. J Cell Mol Med. 2021;25(5):2309–14. https://doi.org/10.1111/jcmm.16296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Li L, Wang R, He S, et al. The identification of induction chemo-sensitivity genes of laryngeal squamous cell carcinoma and their clinical utilization [J]. Eur Arch Otorhinolaryngol. 2018;275(11):2773–81. https://doi.org/10.1007/s00405-018-5134-x.

    Article  PubMed  Google Scholar 

  8. Park JH, Pyun WY, et al. Cancer metabolism: phenotype, signaling and therapeutic targets [J]. Cells. 2020;9(10):2308. https://doi.org/10.3390/cells9102308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vazquez A, Kamphorst JJ, Markert EK, et al. Cancer metabolism at a glance [J]. J Cell Sci. 2016;129(18):3367–73. https://doi.org/10.1242/jcs.181016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Phillips RS. Structure and mechanism of kynureninase [J]. Arch Biochem Biophys. 2014;544:69–74. https://doi.org/10.1016/j.abb.2013.10.020.

    Article  CAS  PubMed  Google Scholar 

  11. Riess C, Schneider B, Kehnscherper H, et al. Activation of the kynurenine pathway in human malignancies can be suppressed by the cyclin-dependent kinase inhibitor dinaciclib [J]. Front Immunol. 2020;11:55. https://doi.org/10.3389/fimmu.2020.00055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Adams S, Teo C, McDonald KL, Zinger A, Guillemin GJ, et al. Involvement of the kynurenine pathway in human glioma pathophysiology [J]. PLoS ONE. 2014;9(11):112945. https://doi.org/10.1371/journal.pone.0112945.

    Article  CAS  Google Scholar 

  13. Gao HY, Luo XG, Chen X, et al. Identification of key genes affecting disease free survival time of pediatric acute lymphoblastic leukemia based on bioinformatic analysis[J]. Blood Cells Mol Dis. 2015;54(1):38–43. https://doi.org/10.1016/j.bcmd.2014.08.002.

    Article  CAS  PubMed  Google Scholar 

  14. Ci C, Wu C, Lyu D, et al. Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway [J]. Clin Exp Dermatol. 2020;45(2):194–201. https://doi.org/10.1111/ced.14072.

    Article  CAS  PubMed  Google Scholar 

  15. Liu Y, Feng X, Lai J, et al. A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer [J]. J Cell Mol Med. 2019;23(10):6700–7. https://doi.org/10.1111/jcmm.14547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang R, Shi H, Ren F, et al. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells [J]. Oncol Rep. 2016;35(4):2466–72. https://doi.org/10.3892/or.2016.4585.

    Article  CAS  PubMed  Google Scholar 

  17. Manoochehri M, Karbasi A, Bandehpour M, et al. Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-fu in colorectal cancer [J]. Pathol Oncol Res. 2014;20(2):301–7. https://doi.org/10.1007/s12253-013-9695-0.

    Article  CAS  PubMed  Google Scholar 

  18. Shi L, Chen J, Yang J, et al. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity [J]. Brain Res. 2010;1352:255–64. https://doi.org/10.1016/j.brainres.2010.07.009.

    Article  CAS  PubMed  Google Scholar 

  19. Sharifi S, Barar J, Hejazi MS, Samadi N. Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel [J]. Asian Pac J Cancer Prev. 2014;15(20):8617–22. https://doi.org/10.7314/apjcp.2014.15.20.8617.

    Article  PubMed  Google Scholar 

  20. Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma [J]. Blood. 2014;123(26):4111–9. https://doi.org/10.1182/blood-2014-03-560284.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We appreciate the support of all laboratory staff.

Funding

This work was funded by the grants of Science and Technology Department of Jiangxi Province (No. 20203BBGL73137). The funding source had no role in the design of this study and interpretation of the data, writing assistance, or decision to submit results.

Author information

Authors and Affiliations

  1. Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, Zhejiang, China

    Jun-wen Zhang

  2. Oncology Department of Jiangxi Maternal and Child Health Care Hospital, No. 318, Bayi Avenue, Nanchang, 330006, Jiangxi, China

    Ya-nan Wang, Mei-ling Zhong & Mei-rong Liang

Authors
  1. Jun-wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ya-nan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei-ling Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mei-rong Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jw Z: designing the study, analyzing the data and devoting to methods. Yn W: devoting to methods. Ml Z: Writing and review of manuscript. Mr L: supervising the study.

Corresponding author

Correspondence to Mei-rong Liang.

Ethics declarations

Ethics approval and consent to participate

This study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of Jiangxi Maternal and Child Health Hospital (No.EC-KT-202230). An exemption of requiring written informed consent has been granted by the ethics committee of Jiangxi Maternal and Child Health Hospital. Animal studies were performed according to the rules for care and use of experimental animals and were approved by the Animal Care Committees Nanchang University (Approval numbers: SYXK(赣)2015–0001).

Consent for publication

Not applicable.

Competing interests

The authors declare that there are no conflicts of interest in regard to this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Jw., Wang, Yn., Zhong, Ml. et al. Kynureninase knockdown inhibits cisplatin resistance in vivo and in vitro and impacts the prognosis of cervical adenocarcinoma. Cell Div 18, 15 (2023). https://doi.org/10.1186/s13008-023-00098-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13008-023-00098-3

Keywords

Cell Division

ISSN: 1747-1028

Contact us